EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY-NC 4.0

A comparison of the safety and effectiveness of insulin aspart with other bolus insulins in women with pre‐existing Type 1 diabetes during pregnancy: A post hoc analysis of a prospective cohort study

Elisabeth R Mathiesen iD, Amra Ciric Alibegovic, Gayathri Anil, Fidelma Dunne iD, Tariq Halasa, Marina Ivanišević, David R McCance, Rikke Baastrup Nordsborg, Peter Damm, EVOLVE study group

Diabetic Medicine · 2024

DOI: 10.1111/dme.15411 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Diabetic Medicine, 2024. Verfasst von Elisabeth R Mathiesen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Pregnant Women with Diabetes, Department of Endocrinology, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin Aspart, Pregnancy in Diabetics, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The safety and efficacy of insulin analogue insulin aspart (IAsp) have been demonstrated in a randomised clinical trial in pregnant women with Type 1 diabetes (T1D), and IAsp is widely used during pregnancy. The aim of this study was to assess glycaemic control and safety of IAsp versus other bolus insulins in Type 1 diabetic pregnancy in a real‐world setting.

Methods

This was a post hoc analysis of a prospective cohort study of 1840 pregnant women with T1D, treated with IAsp ( n = 1434) or other bolus insulins ( n = 406) in the Diabetes Pregnancy Registry. The primary (composite) outcome was the proportion of pregnancies resulting in major congenital malformations or perinatal or neonatal death. Secondary outcomes included all HbA 1c values measured immediately before and during pregnancy and major hypoglycaemia, as well as abortion, pre‐eclampsia, pre‐term delivery, large for gestational age at birth, stillbirth and fetal malformations.

Results

There were no significant differences found in any of the pregnancy outcomes between treatment with IAsp and other bolus insulins in either the crude or propensity score‐adjusted analyses. However, maternal HbA 1c was lower in the IAsp group at the end of the third trimester (adjusted difference, −0.16% point [95% CI −0.28;−0.05]; −1.8 mmol/mol [95% CI −3.1;−0.6]; p = 0.0046).

Conclusions

No significant differences in safety or pregnancy outcomes were demonstrated when comparing treatment with IAsp versus other bolus insulins in women with T1D during pregnancy. The observed improvement in HbA 1c with IAsp in late pregnancy should be confirmed in other studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Insulin AspartPregnancy in DiabeticsHypoglycemic AgentsPregnancy OutcomeGlycated HemoglobinHumansPregnancyFemaleAdultProspective StudiesHypoglycemiaInsulinInfant, NewbornCohort StudiesGlycemic ControlBlood Glucose

Stichwörter der Autor:innen

Type 1 diabetescohort studydiabetes pregnancy outcomesglycated haemoglobininsulin analoguesinsulin aspartpregnant women

Substanzen

Insulin AspartHypoglycemic AgentsGlycated HemoglobinInsulinhemoglobin A1c protein, humanBlood Glucose

Autor:innen und Institutionen

  • Center for Pregnant Women with Diabetes, Department of Endocrinology, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Medical and Science, Novo Nordisk A/S, Søborg, Denmark.
  • Global Medical Affairs, Global Business Services (GMA-GBS), Novo Nordisk Service Centre India Private Limited, Bengaluru, India.
  • College of Medicine Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland.
  • Real-World Science-Diabetes, Novo Nordisk A/S, Søborg, Denmark.

ORCID-Profile: Elisabeth R Mathiesen, Fidelma Dunne

Zitieren

APA

Mathiesen, E. R., Alibegovic, A. C., Anil, G., Dunne, F., Halasa, T., Ivanišević, M., McCance, D. R., Nordsborg, R. B., Damm, P., & EVOLVE study group (2024). A comparison of the safety and effectiveness of insulin aspart with other bolus insulins in women with pre‐existing Type 1 diabetes during pregnancy: A post hoc analysis of a prospective cohort study. Diabetic Medicine. https://doi.org/10.1111/dme.15411

Vancouver

Mathiesen ER, Alibegovic AC, Anil G, Dunne F, Halasa T, Ivanišević M, et al. A comparison of the safety and effectiveness of insulin aspart with other bolus insulins in women with pre‐existing Type 1 diabetes during pregnancy: A post hoc analysis of a prospective cohort study. Diabetic Medicine. 2024. doi:10.1111/dme.15411

BibTeX
@article{Mathiesen2024,
  author = {Mathiesen, Elisabeth R and Alibegovic, Amra Ciric and Anil, Gayathri and Dunne, Fidelma and Halasa, Tariq and Ivanišević, Marina and McCance, David R and Nordsborg, Rikke Baastrup and Damm, Peter and EVOLVE study group, EVOLVE study group},
  title = {A comparison of the safety and effectiveness of insulin aspart with other bolus insulins in women with pre‐existing Type 1 diabetes during pregnancy: A post hoc analysis of a prospective cohort study},
  journal = {Diabetic Medicine},
  year = {2024},
  doi = {10.1111/dme.15411}
}
Kostenlos starten →